Murielle Derrien

Title: Murielle Derrien: Innovator in Engineered Immune Cells

Introduction

Murielle Derrien is a prominent inventor based in Paris, France. She has made significant contributions to the field of immunotherapy, particularly in the development of engineered immune cells. With a total of 2 patents, her work focuses on advancing cancer treatment through innovative technologies.

Latest Patents

One of her latest patents is titled "Universal anti-CD22 chimeric antigen receptor engineered immune cells." This invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) that includes a deletion in the TRAC gene. This modification allows the immune cells to redirect their specificity and reactivity toward selected tumor cells. The engineered immune cells equipped with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

Career Highlights

Murielle works at Cellectis S.A., a company known for its pioneering work in gene editing and immunotherapy. Her role at Cellectis has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of her notable coworkers include Julianne Smith and Philippe Duchateau, who are also involved in advancing the company's innovative projects.

Conclusion

Murielle Derrien's contributions to the field of engineered immune cells highlight her role as a key innovator in cancer treatment. Her patents and work at Cellectis S.A. demonstrate her commitment to improving patient outcomes through advanced therapeutic strategies.